| 产品描述: | CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer |
| 靶点: |
PDGFR |
| 体外研究: |
CT52923 抑制 PDGFRs 和干细胞因子受体,IC50 值为 100 至 200 nM。 CT52923(0.01-30 μM;24 h)阻断血小板衍生生长因子诱导的平滑肌细胞迁移或成纤维细胞增殖,IC50 分别为 64 和 280 nM。 |
| 体内研究: |
CT52923(口服;5、15、30 和 50 mg/kg;每日两次)可显著抑制大鼠颈动脉损伤后内膜新生的形成。 Animal Model: Rat carotid artery balloon angioplasty model. Dosage: 5, 15, 30, and 50 mg/kg Administration: Oral gavage; twice daily Result: Inhibited PDGF-mediated response to vascular injury. |
| 参考文献: |
1. J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298(3):1172-8. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.139 ml |
10.694 ml |
21.389 ml |
| 5 mM |
0.428 ml |
2.139 ml |
4.278 ml |
| 10 mM |
0.214 ml |
1.069 ml |
2.139 ml |
| 50 mM |
0.043 ml |
0.214 ml |
0.428 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |